BiotechTube
Byondis

Byondis

Nijmegen, Netherlands· Est.
byondis.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $105M

Overview

Byondis is a clinical-stage biotech developing a proprietary pipeline of antibody-drug conjugates (ADCs) for oncology, anchored by its lead asset, [vic-]trastuzumab duocarmazine (SYD985). The company leverages its internal ADC platform, including its proprietary linker-payload technology (duocarmycin-based), to create targeted therapies. While it faced a significant setback with a Complete Response Letter from the FDA for its lead candidate in HER2-positive metastatic breast cancer, Byondis continues to advance other pipeline programs and explore strategic options, including partnerships or out-licensing, to realize the value of its technology.

Oncology

Technology Platform

Proprietary antibody-drug conjugate (ADC) platform featuring a cleavable linker and a duocarmycin-based cytotoxic payload (seco-DUBA) designed for targeted delivery and intracellular release.

Funding History

3
Total raised:$105M
Debt$25M
Series B$50M
Series A$30M

Opportunities

The rapidly expanding ADC market, validated by multiple blockbusters, presents a significant opportunity for novel linker-payload technologies.
Byondis's platform could be applied to new targets or used to improve upon existing ADCs, creating partnership potential.
Resolving the CMC issues for SYD985 could unlock value in a large oncology market.

Risk Factors

The Complete Response Letter for lead asset SYD985 poses a major regulatory and financial risk, delaying potential revenue and requiring additional resources.
As a pre-revenue private company, securing further funding is critical and challenging.
Intense competition in the ADC space threatens commercial viability even if approval is achieved.

Competitive Landscape

Byondis operates in the highly competitive field of antibody-drug conjugates, facing large, established players like AstraZeneca/Daiichi Sankyo (Enhertu), Roche (Kadcyla, Polivy), and Gilead (Trodelvy). Its differentiation relies on its duocarmycin payload technology, but it must demonstrate superior efficacy or safety to gain market share against these well-funded competitors with advanced commercial infrastructures.

More companies in Biologics / Biosimilars →More companies in Netherlands →